Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
A total of 142 patients underwent randomization. At week 104, complete remission was observed in 26 of 71 patients in the obinutuzumab group and in 4 of 70 patients in the tacrolimus group (37% vs. 6% with multiple imputation for missing data; adjusted difference, 31 percentage points; 95% CI, 18 to 44; P<0.001). Obinutuzumab was superior to tacrolimus in inducing complete remission in patients with primary membranous nephropathy.
Category
News
Source
The New England Journal of Medicine
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.